Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
about
Wnt/beta-catenin signaling and small molecule inhibitorsThe molecular rationale of Src inhibition in colorectal carcinomasAndrogen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinasesPharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studySafety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012.Drug combination therapy increases successful drug repositioning.The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins.Drug monographs: bosutinib and regorafenib.Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspectiveBosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer.Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problemsAn overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.Design considerations for dose-expansion cohorts in phase I trialsBosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.Drug-drug interaction between bosutinib and warfarin.A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia.Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
P2860
Q24597197-145A9CD8-FC49-446F-8B47-A30A54DAE555Q26853018-ACAC49F9-4303-457D-B58F-694AB09ECC9DQ26866135-E4532BFB-0648-49E7-8074-67828CFF3815Q33403826-8664E54B-8AAC-4D15-A267-348E58F44C3AQ34103108-7C09A815-51D7-4F62-83AE-42ED07A59DB9Q34658293-CC757B99-1DD6-48EE-93A0-8ECC48BA64D7Q35008618-8E52DC7F-E928-45AF-A9C7-7FB7056AD28FQ35070978-20257A60-E767-4B91-8473-4552E7CC1724Q35376207-8AA9CB70-D4AB-41FA-9DA9-C026285D1BC9Q37004251-EFD2089D-71D4-440E-B8B3-8CE1458C22D5Q37060125-08EE47F5-843D-4AEF-BB3F-4F4574A89041Q37340111-3FF2D93E-A550-45AF-AD32-9BA6A0FA62A2Q37580148-5BE1C2A2-EFDB-4137-99EE-E455541ECE29Q37596010-5202DBF2-8D53-4A18-8F0F-E51AAE801427Q38076275-642A157C-5134-41BC-B6A8-C24EB8E1ABFBQ38554714-2B1A6D49-98C3-415E-AA8B-E62FA311617CQ38817367-CEB324C4-A3B5-4B9D-ADD3-F144B03ECF13Q41895594-6D2491D3-FAE7-4A0F-9517-D292DBF7195EQ46220838-47CD2EB9-748B-490A-B4F5-D16DAAC45340Q50041888-B2A3426D-C240-40A7-8DB1-C09C50046610Q50068063-895D0515-8FDB-47CE-8DD6-7C5C317D90E7Q53077200-0809D3C8-B5BB-475F-B4D4-F0EB66A6102AQ53659325-65A422D0-E7CC-42EB-A1CD-23793C2BEC54Q54478532-418567D5-A021-45AD-800A-11DAA84DFAEF
P2860
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase I study of bosutinib, a ...... ts with advanced solid tumors.
@ast
Phase I study of bosutinib, a ...... ts with advanced solid tumors.
@en
Phase I study of bosutinib, a ...... ts with advanced solid tumors.
@nl
type
label
Phase I study of bosutinib, a ...... ts with advanced solid tumors.
@ast
Phase I study of bosutinib, a ...... ts with advanced solid tumors.
@en
Phase I study of bosutinib, a ...... ts with advanced solid tumors.
@nl
prefLabel
Phase I study of bosutinib, a ...... ts with advanced solid tumors.
@ast
Phase I study of bosutinib, a ...... ts with advanced solid tumors.
@en
Phase I study of bosutinib, a ...... ts with advanced solid tumors.
@nl
P2093
P1476
Phase I study of bosutinib, a ...... nts with advanced solid tumors
@en
P2093
Barbara J Gitlitz
Charles Zacharchuk
Elena G Chiorean
Gregory M Springett
Kathleen Turnbull
Mansoor N Saleh
Mitesh J Borad
Nathalie Bardy-Bouxin
Philip J Gold
P304
P356
10.1158/1078-0432.CCR-11-2378
P407
P50
P577
2011-12-16T00:00:00Z